SCHEMBL2904969

SCHEMBL2904969

COc1ccc(NC(c2cccnc2)c2cccc(Cl)c2)cc1C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
MAPK1 P28482 1/20 0.42
CSF1R P07333 1/20 0.42
TRPM8 Q7Z2W7 2/20 0.41
RPS6KB1 P23443 2/20 0.41
AURKA O14965 1/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HSP90AA1 P07900 1/20 0.41
MAPT P10636 1/20 0.41
KCNMA1 Q12791 1/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
ALPL P05186 2/20 0.40
SGMS2 Q8NHU3 1/20 0.40
LMNA P02545 1/20 0.40
SYK P43405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908801 0.92 MKNK1 (0.50) MKNK1MKNK2MAPK1CSF1RTRPM8
SCHEMBL2908503 0.75 RCE1 (0.50) MAPK1GAAKMT2AALDH1A1MAPT
SCHEMBL2907010 0.74 NPC1 (0.45) MAPK1KMT2AALDH1A1MAPTLMNA
SCHEMBL2908203 0.73 MKNK1 (0.45) MKNK1MKNK2MAPK1CSF1RGAA
SCHEMBL2905934 0.71 RCE1 (0.50) MAPK1TRPM8GAAALDH1A1LMNA
SCHEMBL2909821 0.71 LMNA (0.45) MAPK1TRPM8GAAKDM4EALDH1A1
SCHEMBL20655800 0.69 MAPT (0.47) MAPK1KDM4EKMT2AALDH1A1MAPT
SCHEMBL2904970 0.69 MKNK1 (0.45) MKNK1MKNK2MAPK1ALDH1A1HCRTR1
SCHEMBL3131362 0.68 KDM4E (0.60) MAPK1GAAKDM4EKMT2AALDH1A1
SCHEMBL726267 0.67 MAPT (0.60) MAPK1GAAKDM4EKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US claimed
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
EP-1692109-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS Memory Pharmaceuticals Corporation (US) 2006-08-23 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B MKNK1 4229/4885MKNK2 4117/4885MAPK1 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.